U.S. health officials are asking retailers to pull a small number of acne creams from their store shelves after government ...
Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...
Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to ...
Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...
Parent company La Roche-Posay has pulled the Effaclar Duo Acne Spot Treatment from L'Oreal's lineup, due to a cancer-causing ...
Some three years after the University of Pennsylvania claimed four of Roche’s breast cancer meds infringed its intellectual ...
Acne creams from retailers including Walgreens, La Roche-Posay and Proactiv have been voluntarily recalled due to elevated levels of a potentially cancer-causing agent.
Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor ...
Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...
The FDA tested 95 products containing benzoyl peroxide, an ingredient widely used to treat acne that can form benzene as a byproduct. It found that six products could have more benzene than usual.
Swiss pharmaceutical company Roche struck a multibillion-dollar collaboration and licensing deal with Zealand Pharma to co-develop a weight-loss treatment. Roche's stock rallied in Europe, while ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results